Risk Assessment and Minimization for Progressive Multifocal Leukoencephalopathy (PML RAMP): A Program to Assess for Potential Early Signs and Symptoms of PML during Clinical Development of Vedolizumab
David Clifford(Washington University in St. Louis), Asit Parikh, Joseph Berger, Eric S. Freedland, Michael H. Lev(Massachusetts General Hospital), Catherine Milch(Millennium Engineering and Integration (United States)), Serap Sankoh(Millennium Engineering and Integration (United States)), Megan McAuliffe(Takeda (Japan)), Eugene O. Major, James Provenzale(University of Alabama at Birmingham Hospital), Kristin Stephens(Millennium Engineering and Integration (United States)), Irving H. Fox(Takeda (United States))
Cited by 8
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Recommendations on Angiographic Revascularization Grading Standards for Acute Ischemic Stroke
|Stroke|2013|1.7k
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
|New England Journal of Medicine|2006|792